论文部分内容阅读
目的探讨丁苯酞软胶囊协同抗抑郁药治疗对急性脑梗死(Acute cerebral infarct,ACI)后抑郁患者情绪障碍及脑功能恢复的影响。方法选取2016年3月~2017年3月本院收治ACI合并抑郁患者150例,根据随机数字表法随机分为观察组(n=75)和对照组(n=75)。对照组在常规ACI治疗基础上口服盐酸舍曲林片治疗,观察组在常规ACI治疗基础上口服丁苯酞软胶囊+盐酸舍曲林片治疗。比较两组治疗临床疗效、美国国立卫生院脑卒中量表(NIHSS)和中国卒中量表(CSS)评分、汉密尔顿抑郁量表(HAMD)和抑郁自评量表(SDS)评分、药物不良反应。结果观察组总有效率为94.67%,对照组总有效率为82.67%,差异有统计学意义(P<0.05);观察组治疗后不同时间点NIHSS和CSS评分,HAMD和SDS评分均显著低于对照组(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论丁苯酞软胶囊协同抗抑郁药治疗ACI后抑郁症患者安全有效,不仅可改善患者抑郁状态,还可促进患者神经功能恢复。
Objective To investigate the effects of butylphthalide soft capsule synergistic antidepressants on mood disorders and recovery of brain function in patients with depression after acute cerebral infarction (ACI). Methods 150 patients with ACI combined depression in our hospital from March 2016 to March 2017 were randomly divided into observation group (n = 75) and control group (n = 75) according to the random number table method. The control group was treated with sertraline hydrochloride orally on the basis of routine ACI treatment. The observation group was treated with butylphthalide soft capsule and sertraline hydrochloride orally on the basis of routine ACI treatment. The clinical efficacy, NIHSS and CSS scores, Hamilton Depression Rating Scale (HAMD) and Depression Self-rating Scale (SDS) were compared between the two groups. Adverse reactions were observed. Results The total effective rate was 94.67% in the observation group and 82.67% in the control group, the difference was statistically significant (P <0.05); NIHSS and CSS scores, HAMD and SDS scores of the observation group were significantly lower than those of the control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Butylphthalide soft capsule synergistic antidepressants in the treatment of depression patients after ACI safe and effective, not only can improve the patient’s depression, but also to promote neurological recovery.